$PRXL (PAREXEL International Corporation)

$PRXL {{ '2016-09-26T13:47:11+0000' | timeago}} • Announcement

$PRXL agreed to buy ExecuPharm, a global functional service provider (FSP) serving the biopharmaceutical industry, for undisclosed terms. The acquisition is expected to close in the next three weeks.

$AMGN {{ '2017-07-25T22:44:31+0000' | timeago}} • Announcement

$AMGN increased its 2017 earnings guidance to between $10.79 per share and $11.37 per share on GAAP basis, and between $12.15 per share and $12.65 per share on adjusted basis. Sales guidance was revised to a range of $22.5-23Bil.

$AMGN {{ '2017-07-25T22:43:15+0000' | timeago}} • Announcement

$AMGN reported a 15% YoY earnings growth in 2Q17 to $2.2Bil, or $2.91 per share, driven by a 4.9 percentage points increase in operating margin. Adjusted for one-time items, the company reported per-share earnings of $3.27. Revenue rose 2% to $5.8Bil.

$AMGN {{ '2017-07-25T20:50:47+0000' | timeago}} • Infographic

$AMGN Amgen Earnings AlphaGraphic: Q2 2017 highlights

$LLY {{ '2017-07-25T15:33:57+0000' | timeago}} • Announcement

$LLY and its development and marketing partner $INCY announced that resubmission of rheumatoid arthritis drug baricitinib will be delayed beyond 2017 and at least it will take 18 months. FDA has demanded for a new trial. ELi Lilly added that baricitinib tablets have been approved since Feb 2017 in EU and the drug was approved recently in Japan.

$NLSN {{ '2017-07-25T15:16:03+0000' | timeago}} • Announcement

$NLSN has tied up with Chinese e-commerce firm JD.com for the collaborative launch of a Multi-Touch Attribution (MTA) offering in China. As part of the deal, both companies will jointly market the MTA offering to help marketers better determine the effectiveness and return on investment of ads both in and outside of JD.com.

$IBM {{ '2017-07-21T17:53:42+0000' | timeago}} • Announcement

$IBM and University of Alberta published new data in Nature's partner journal Schizophrenia, exhibiting that machine learning algorithms helped predict schizophrenia with 74% accuracy. The technology predicted the severity of some symptoms in schizophrenia patients with significant correlation.

$MSFT {{ '2017-07-21T12:34:48+0000' | timeago}} • Announcement

$MSFT's Intelligent Cloud unit revenue grew 11% in 4Q17, boosted by growth in server products and cloud services. Revenue of server products and cloud services was up 15%, while Azure, the software giant's cloud platform, surged 97%. Last week, $MSFT announced that $DNB and Chinese Internet firm $BIDU will use Azure for their cloud computing needs.

$NLSN {{ '2017-07-20T18:54:03+0000' | timeago}} • Announcement

$NLSN declared a quarterly cash dividend of $0.34 per share of common stock. The dividend is payable on September 7, 2017 to stockholders of record at the close of business on August 24, 2017.

$INCY {{ '2017-07-20T13:24:37+0000' | timeago}} • Announcement

$INCY said first patient has been treated in Phase 3 trial of itacitinib for the first-line treatment of patients with acute graft-versus-host disease (GVHD). GVHD is a condition that might occur after an allogeneic transplant, whereby the donated bone marrow or peripheral blood stem cells view the recipient’s body as foreign and attack the body.

$MSFT {{ '2017-07-19T21:56:12+0000' | timeago}} • Announcement

$MSFT and $DNB announces a strategic partnership. $DNB will use Microsoft Azure as its cloud platform. Dun & Bradstreet data will be made available through Microsoft Dynamics 365, a cloud-powered service, and the Microsoft’s Common Data Service. Also, the tech giant and D&B will enter into a co-selling arrangement beginning later this year.

$IBM {{ '2017-07-19T19:00:41+0000' | timeago}} • Webcast

$IBM expects improved revenue and gross margin performance in 2H17, pushed by its new IBM z systems mainframe servers launch in 2Q17. However, the company expects most of the growth to happen in 4Q17.

$DNB {{ '2017-07-19T14:40:03+0000' | timeago}} • Announcement

$DNB said it is teaming up with $MSFT to give companies worldwide direct access to its data through $MSFT's cloud services. $DNB has selected $MSFT as a strategic cloud provider to accelerate the company's digital transformation and deliver its customers more efficient and seamless access to its commercial data.

$IBM {{ '2017-07-18T23:42:39+0000' | timeago}} • Announcement

$IBM maintained its FY17 EPS and cash flow expectations. The company continues to expect adjusted diluted EPS of at least $13.80 and GAAP diluted EPS of at least $11.95. Free cash flow is expected to be relatively flat year-to-year.

$IBM {{ '2017-07-18T23:35:37+0000' | timeago}} • Announcement

Big Blue $IBM reported 21st consecutive quarter of revenue decline, with 2Q17 earnings declining 7%. The decline was driven by all segments reporting a decline in revenue YoY. Net income was $2.3Bil or $2.48 per share in 2Q17, down from $2.5Bil or $2.61 per share a year ago. Revenue declined 4.7% to $19.3Bil.

$IBM {{ '2017-07-18T21:07:52+0000' | timeago}} • Infographic

$IBM International Business Machines Earnings AlphaGraphic: Q2 2017 Highlights

$AMGN {{ '2017-07-18T15:11:19+0000' | timeago}} • Announcement

$AMGN and $ARRY collaborates for the discovery and development of novel drugs for autoimmune disorders. The undisclosed target and lead inhibitors were discovered through Array's proprietary platform. Amgen, responsible for clinical development & commercialization, will make upfront and milestone payments for rights to Array's preclinical program.

$LH {{ '2017-07-18T13:30:08+0000' | timeago}} • Announcement

Insurance company $LH said its CEO William Hanlon has been appointed as a member of the governing committee of the National Evaluation System for Health Technology Coordinating Center. Hanlon has been focused on early and late-stage clinical development, as a regulatory affairs expert, for the past several years.

$AMGN {{ '2017-07-14T16:06:47+0000' | timeago}} • Announcement

$AMGN announced the submission of a supplemental New Drug Application to the FDA and a variation to the marketing application to the European Medicines Agency to include overall survival data from the Phase 3 head-to-head ENDEAVOR trial in the product information for KYPROLIS (carfilzomib).

$AMGN {{ '2017-07-13T12:24:26+0000' | timeago}} • Announcement

$AMGN and $AGN announced they will discuss data supporting the ABP 215 Biologics License Application (BLA) with FDA's Oncologic Drugs Advisory Committee. ABP 215 is a biosimilar candidate to Avastin (bevacizumab) and is the first bevacizumab biosimilar candidate to be considered by the FDA.

$AMGN {{ '2017-07-12T20:58:00+0000' | timeago}} • Announcement

$AMGN said the final analysis of its phase-3 ASPIRE trial involving myeloma patients met the key secondary endpoint of overall survival. The study demonstrated Kyprolis reduced the risk of death by 21%, compared to lenalidomide and dexamethasone. The data will be submitted to regulatory agencies to support a potential label update.

Recent Transcripts

AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm
IBM (International Business Machines Corporation)
Tuesday, July 18 2017 - 9:00pm
INFY (Infosys Limited)
Friday, July 14 2017 - 12:30pm
INFY (Infosys Limited)
Friday, July 14 2017 - 6:00am
ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
CCXI (ChemoCentryx, Inc.)
Wednesday, May 10 2017 - 9:00pm
XON (Intrexon Corporation)
Wednesday, May 10 2017 - 8:30pm
CRL (Charles River Laboratories International, Inc.)
Wednesday, May 10 2017 - 12:30pm
CTSH (Cognizant Technology Solutions Corporation)
Friday, May 5 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
INCY (Incyte Corporation)
Thursday, May 4 2017 - 2:00pm
PRXL (PAREXEL International Corporation)
Thursday, May 4 2017 - 2:00pm
Q (Quintiles Transnational Holdings Inc.)
Wednesday, May 3 2017 - 1:00pm
DNB (Dun & Bradstreet Corp.)
Tuesday, May 2 2017 - 12:00pm
EXEL (Exelixis, Inc.)
Monday, May 1 2017 - 9:00pm
SNMX (Senomyx Inc.)
Thursday, April 27 2017 - 9:00pm
CERN (Cerner Corporation)
Thursday, April 27 2017 - 8:30pm
EXAS (Exact Sciences Corporation)
Thursday, April 27 2017 - 2:00pm
ICLR (ICON Public Limited Company)
Thursday, April 27 2017 - 1:00pm

AlphaGraphics you may like